Diabetes is a growing disease and an enormous global burden that is projected to affect more than 592 million people by 2035. AstraZeneca is pushing the boundaries of science with the goal of developing life-changing medicines that aim to reduce the global burden and complications of diabetes.
Our commitment to diabetes is exemplified by the depth and breadth of our global clinical research program. AstraZeneca is committed to advancing understanding of the treatment effects of our diabetes medicines in broad patient populations, as well as exploring combination treatment approaches to help more patients achieve treatment success earlier in their disease progression. Our ambition is to reduce the long-term impact of diabetes. As a core strategic area for the company, we are focusing our research and development efforts in diverse populations and patients with significant co-morbidities, such as cardiovascular disease, heart failure, obesity, non-alcoholic steatohepatitis (NASH), and chronic kidney disease.
Type 2 diabetes is a metabolic disorder characterised by chronically high levels of glucose in the blood. Find out more about the condition and its prevalence.
Bydureon (exenatide extended-release injectable suspension) is a once-weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist available as a single-dose tray or a single-dose pen indicated to improve glycaemic control, in adults with Type 2 diabetes. Available as 2mg powder and solvent for prolonged release suspension for injection.
Forxiga (dapagliflozin) Forxiga is a highly selective SGLT2 inhibitor for Type 2 diabetes that removes glucose and its associated calories via the kidney.
Onglyza (saxagliptin) is indicated in adult patients aged 18 years and older with Type 2 diabetes mellitus to improve glycaemic control.
QTERN▼ (saxagliptin/dapagliflozin) is for patients on metformin and Forxiga (dapagliflozin) who require additional HbA1c reduction.
GB-8117 - September 2017